Pharmacokinetic analyses
BLOOD
Blood samples were collected prior to and after dosing on days 1 and 10 for measurement of plasma baxdrostat and CIN-107-M concentrations to characterize single-dose and steady-state PK. Pharmacokinetic parameters were calculated by standard noncompartmental methods using Phoenix WinNonlin™ (Certara, Inc., Princeton, NJ) and verified with SAS (SAS Institute, Inc., Cary, NC) software. Plasma PK parameters included maximum observed plasma concentration on day 1 (CThe cumulative amount of drug excreted in urine on day 1 (A